Organization, Nature of Business, and Liquidity (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) Women	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) Product Women Segment	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Organization and Nature of Business [Abstract]
Number of operating segments | Segment			1
Number of products received EU MDR and CE Mark certifications | Product			4
Number of women used FemBloc for permanent birth control | Women	401		401
Number of year where women's used for permanent birth control.			1 year
Number of women enrolled for a clinical readout | Women			50
Number of women need to use for interim analysis of clinical data for permanent birth control | Women			300
Period for analysis of clinical data for permanent birth control			1 year
Follow-up period for interim analysis of clinical data for permanent birth control			5 years
Liquidity [Abstract]
Cash and cash equivalents | $	$ 13,525,898		$ 13,525,898		$ 21,716,077
Net loss | $	(4,684,574)	$ (2,893,508)	(8,284,084)	$ (5,839,765)
Accumulated deficit | $	$ (116,665,713)		$ (116,665,713)		$ (108,381,629)